Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database
-
By
-
Jing Chen
-
Lilan Zhao
-
June 5, 2026
-
Clinical Scorecard: Evaluating the Association Between Medications and Aggression in Children: Insights from the FAERS Database Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Drug-associated aggression may exacerbate pre-existing behavioral problems or arise de novo following medication exposure. [Source needed] |
| Target Population | |
| Care Setting | |
Key Highlights
- Ebastine and perampanel showed the strongest signals for aggression. [Source needed]
Guideline-Based Recommendations
Diagnosis
Management
- C
- o
- n
- s
- i
- d
- e
- r
-
- d
- e
- m
- o
- g
- r
- a
- p
- h
- i
- c
- -
- s
- p
- e
- c
- i
- f
- i
- c
-
- r
- i
- s
- k
- s
-
- w
- h
- e
- n
-
- p
- r
- e
- s
- c
- r
- i
- b
- i
- n
- g
-
- m
- e
- d
- i
- c
- a
- t
- i
- o
- n
- s
- .
-
- [
- S
- o
- u
- r
- c
- e
-
- n
- e
- e
- d
- e
- d
- ]
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Children and adolescents under 18 years of age.
Commonly implicated medications include psychotropic drugs like fluoxetine and stimulants like methylphenidate.
Clinical Best Practices
- Update regulatory labeling to improve pediatric drug safety. [Source needed]
Related Resources & Content
